Axsome Therapeutics Inc (AXSM)
87.15
-1.69
(-1.90%)
USD |
NASDAQ |
Nov 04, 16:00
87.16
+0.01
(+0.01%)
After-Hours: 20:00
Axsome Therapeutics Enterprise Value: 4.047B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 4.047B |
| November 01, 2024 | 4.128B |
| October 31, 2024 | 4.137B |
| October 30, 2024 | 4.158B |
| October 29, 2024 | 4.200B |
| October 28, 2024 | 4.189B |
| October 25, 2024 | 4.177B |
| October 24, 2024 | 4.128B |
| October 23, 2024 | 4.295B |
| October 22, 2024 | 4.299B |
| October 21, 2024 | 4.256B |
| October 18, 2024 | 4.344B |
| October 17, 2024 | 4.344B |
| October 16, 2024 | 4.182B |
| October 15, 2024 | 4.012B |
| October 14, 2024 | 3.964B |
| October 11, 2024 | 4.067B |
| October 10, 2024 | 3.852B |
| October 09, 2024 | 3.874B |
| October 08, 2024 | 3.935B |
| October 07, 2024 | 3.903B |
| October 04, 2024 | 4.020B |
| October 03, 2024 | 4.240B |
| October 02, 2024 | 4.339B |
| October 01, 2024 | 4.208B |
| Date | Value |
|---|---|
| September 30, 2024 | 4.177B |
| September 27, 2024 | 4.166B |
| September 26, 2024 | 4.166B |
| September 25, 2024 | 4.180B |
| September 24, 2024 | 4.247B |
| September 23, 2024 | 4.259B |
| September 20, 2024 | 4.464B |
| September 19, 2024 | 4.391B |
| September 18, 2024 | 4.258B |
| September 17, 2024 | 4.229B |
| September 16, 2024 | 4.299B |
| September 13, 2024 | 4.360B |
| September 12, 2024 | 4.268B |
| September 11, 2024 | 4.233B |
| September 10, 2024 | 4.313B |
| September 09, 2024 | 4.380B |
| September 06, 2024 | 4.337B |
| September 05, 2024 | 4.361B |
| September 04, 2024 | 4.451B |
| September 03, 2024 | 4.167B |
| August 30, 2024 | 4.129B |
| August 29, 2024 | 4.141B |
| August 28, 2024 | 4.108B |
| August 27, 2024 | 4.132B |
| August 26, 2024 | 4.112B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
657.91M
Minimum
Aug 19 2021
4.464B
Maximum
Sep 20 2024
2.556B
Average
2.673B
Median
Apr 12 2023
Enterprise Value Benchmarks
| Krystal Biotech Inc | 4.349B |
| Pfizer Inc | 219.16B |
| Sarepta Therapeutics Inc | 11.50B |
| Moderna Inc | 12.09B |
| NovaBay Pharmaceuticals Inc | 3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -79.34M |
| Revenue (Quarterly) | 87.17M |
| Total Expenses (Quarterly) | 163.05M |
| EPS Diluted (Quarterly) | -1.67 |
| Gross Profit Margin (Quarterly) | 90.76% |
| Profit Margin (Quarterly) | -91.03% |
| Earnings Yield | -7.47% |
| Normalized Earnings Yield | -6.413 |